A series of heptamethine cyanine (1-3) derivatives bearing a carbamate ethyl disulfide group and gemcitabine, an anticancer drug, have been newly synthesized. Their disulfide bonds are readily cleaved by various thiols including glutathione, to result in a subsequent decomposition of the carbamate into amine followed by release of the active gemcitabine, which can be monitored by the fluorescence changes. In the biological experiment, prodrug 1 is preferentially up-taken by folate-positive KB cells over folate-negative A549 cells via receptor-mediated endocytosis to release gemcitabine causing cell death and to emit fluorescence in endoplasmic reticulum. Moreover, it is selectively accumulated in the KB cells which were treated to mice by dorsal subcutaneous injection. This drug delivery system is a new theranostic agent, wherein both therapeutic effect and drug uptake can be easily monitored at the subcellular level, by in vivo and in vitro fluorescence imaging.
Compounds of Formula I, or pharmaceutically acceptable salts thereof:
wherein R
1
, R
2
, R
3
, R
4
, m, n, q, s, t, X, and Y are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.
Intramolecular β-Alkenylation of Cyclohexanones via Pd-Catalyzed Desaturation-Mediated C(sp<sup>3</sup>)–H/Alkyne Coupling
作者:Chengpeng Wang、Nevin A. Naren、Pengfei Zheng、Guangbin Dong
DOI:10.1021/jacs.0c02654
日期:2020.5.13
through direct coupling of C(sp3)-H bonds with unsaturated hydrocarbons represents an atom-economical and redox-neutral way for functionalizing chemically inert positions, such as those β to a carbonyl group. While most existing β-functionalization methods utilize a directing group (DG) strategy, here we report a Pd-catalyzed intramolecular β-alkenylation of ketones using alkynes as the coupling partner without
manipulation of this hypoxia‐dependent photocaging and dual‐modal optical signals in livingcells and tumor‐bearing mice, making a breakthrough in the direct spatiotemporalcontrol and in vivo feedback regulation. This unique photoactivation mechanism overcomes the limitation of hypoxia, which allows site‐specific remote control for targeted therapy, and expands the photo‐trigger toolbox for on‐demand drug
two butadiynyl monomers: symmetrical 5,5′-[hexa-2,4-diyne-1,6-diylbis(oxy)]bis(oxepan-2-one) (3-C4-3) and unsymmetrical 5-[5-(trimethylsilyl)penta-2,4-diyn-1-yl]oxy}oxepan-2-one (3-C4TMS) via Eglinton and Cadiot–Chodkiewicz couplings, respectively. Both compounds were obtained through an alternative Baeyer–Villiger oxidation of immediate ketone precursors 2-C4-2 and 2-C4TMS.
BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE
申请人:COOPER David Gwyn
公开号:US20120041028A1
公开(公告)日:2012-02-16
Compounds of formula (I), salts and solvates are provided:
Uses of the compounds for therapy, for example in the treatment of psychotic disorders and cognitive impairment, are also disclosed.